Why the study?
Do NR3C2 genetic polymorphisms affect the blood pressure response to enalapril in patients with essential hypertension?
Do NR3C2 genetic polymorphisms affect the blood pressure response to enalapril in patients with essential hypertension?
The NR3C2 rs5522 polymorphism significantly affects the diastolic blood pressure response to enalapril, suggesting its potential as a pharmacogenomic marker in essential hypertension.
NR3C2 rs5522 AA genotype was associated with greater DBP reduction on enalapril; leaves open whether genotyping should guide therapy in hypertension.
AIM: The mineralocorticoid receptor (MR; also known as NR3C2) plays important roles in the modulation of blood pressure. The effect of NR3C2 polymorphisms on antihypertensive response to enalapril was investigated. PATIENTS & METHODS: Two hundred and seventy nine essential hypertension patients treated with enalapril were genotyped for two NR3C2 tagSNPs, rs5522 and rs2070950, by Sequenom MassArray™ technology. RESULTS: The reductions in diastolic blood pressure (DBP) were significantly greater in AA homozygotes compared with AG+GG genotype carriers for the rs5522 polymorphism (p = 0.009), and the reductions in DBP were greater in GG homozygotes compared with GC+CC genotype carriers for the rs2070950 polymorphism, with marginal significance (p = 0.065). Stepwise multiple regression analysis indicated that significant predictors of DBP reduction were baseline DBP (p < 0.001), waist:hip ratio (p = 0.001) and rs5522 genotype (p = 0.003). CONCLUSION: NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to enalapril in essential hypertension patients.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: